Garber Alan M 4

What Happened

• Alan M. Garber, a director of Vertex Pharmaceuticals (VRTX), was granted a total of 1,905 shares/RSUs on May 1, 2026. The filing shows two award entries: 472 shares acquired at $0.00 and 1,433 derivative shares acquired at $0.00 (total value recorded as $0 in the filing because these are equity awards, not a purchase).
• These are awards (transaction code A), not open-market purchases or sales, so they reflect compensation/award activity rather than a market buy or sell.

Key Details

• Transaction date: May 1, 2026; Form 4 filed: May 5, 2026 (timely filed within the required reporting window).
• Items reported: 472 shares (award) and 1,433 derivative shares (award) — total 1,905.
• Prices and values: both entries listed at $0.00 in the filing (standard for grant/award entries).
• Footnotes provided in the filing: F1 — an RSU award that vests, subject to limited exceptions, on the first anniversary of the grant date; F2 — fully vested. (The filing notes both footnotes; see filing for which line each footnote applies.)
• Shares owned after the transaction: not specified in the supplied summary of the Form 4.

Context

• These entries are equity awards (RSUs/derivative awards). Awards can vest immediately (fully vested) or over time (e.g., vests on first anniversary); vested awards confer ownership while unvested RSUs do not until vesting conditions are met.
• Awards are routine compensation for directors/executives and do not necessarily signal a buy or sell decision. They differ from purchases (potential bullish signal) or sales (liquidity/other reasons).